CYP19A1 rs1062033 — The Aromatase Regulatory Switch and Bone Health
Aromatase — encoded by CYP19A1 on chromosome 15 — is the enzyme that converts
androgens (testosterone, androstenedione) into estrogens (estradiol, estrone) in
peripheral tissues. Unlike the ovaries and testes, which produce estrogen in bulk,
bone, fat, liver, brain, and breast tissue rely on local aromatase activity to
maintain estrogen sufficiency around individual cells. rs1062033 sits approximately
12 kilobases upstream of the CYP19A1 translation start site in a regulatory
region that controls which tissues express aromatase and in what amounts. This
variant alters the binding of
CEBPβ | CCAAT/enhancer-binding protein beta, a transcription factor that regulates
tissue-specific gene expression
to the promoter, producing allele-specific differences in aromatase expression that
downstream affect local estrogen concentrations — particularly in bone.
The Mechanism
The rs1062033 C>G change lies in an intronic regulatory region of CYP19A1 that acts
as a tissue-specific promoter element. Electrophoretic mobility shift assays
demonstrated that the C and G alleles bind the CEBPβ transcription factor with
different affinities, and transient transfection experiments in osteoblastic cells
showed allele-specific differences in luciferase reporter activity when a CEBPβ
expression vector was co-introduced. Critically, differential allelic expression was
confirmed directly in human bone tissue samples — not just in cell culture — making
this one of the few CYP19A1 regulatory variants with direct in-tissue functional
evidence rather than predicted regulatory effects alone.
The practical consequence flows through estrogen's effects on bone remodeling:
estradiol suppresses osteoclast activity (bone breakdown) and supports osteoblast
survival (bone formation). Women with alleles that sustain higher local aromatase
activity in bone cells maintain greater estrogen-driven bone protection even as
circulating ovarian estrogen declines after menopause. The interaction with vitamin D
and calcium is indirect: estrogen upregulates calcium absorption in the gut (via
calcium-binding protein calbindin-D9k | CALB1)
and reduces urinary calcium loss — so allele-driven differences in aromatase activity
propagate into effective calcium and vitamin D utilization in bone.
The Evidence
The foundational study by
Riancho et al. 2009 | J Bone Miner Res — 1,163 postmenopausal women; rs1062033 as
a true regulatory polymorphism with CEBPβ-binding evidence and allele-specific expression
in human bone
showed that opposing homozygotes (CC vs. GG) differed by 4.2% in whole-cohort BMD,
a difference that expanded to 7.3% in women older than 67 — the age group with the
greatest cumulative loss of ovarian estrogen support. This dose-response pattern
across age is consistent with a lifetime accumulation of allele-driven differences
in local bone estrogen signaling.
A Chinese Han case-control study
Chen et al. 2024 | Bladder cancer; 217 cases, 550 controls; OR=0.36 for G vs. C,
FDR-p<0.001; rs1062033 correlated with CYP19A1 expression in whole blood
independently confirmed that rs1062033 modifies CYP19A1 expression levels in blood,
and found the G allele strongly protective against bladder cancer — a tissue where
estrogen signaling is known to influence carcinogenesis risk.
The variant also modifies hormone circulating levels in response to environmental
exposures.
Kopp et al. 2016 | BMC Cancer — 687 cases/controls; rs1062033 associated with
estrone sulphate levels (p=0.007) and interacted with alcohol to influence circulating
hormone concentrations (p-interaction=0.03)
demonstrated that the genotype influences baseline circulating estrone sulphate
independently of hormone replacement therapy, and that the gene-environment
interaction with alcohol is allele-specific.
Practical Actions
The primary clinical implication of this variant is in bone health for postmenopausal
women. Carriers of two C alleles have lower aromatase-driven local estrogen in bone
tissue, particularly relevant after menopause when peripheral aromatization becomes
the dominant estrogen source. For these individuals, optimizing the cofactors that
amplify bone-protective signaling — adequate vitamin D for calcium absorption, calcium
intake distributed across meals for absorption efficiency, and weight-bearing activity
to provide mechanical stimulus — becomes more important than for GG carriers, who
retain higher local aromatase expression. Bone density monitoring starting from
perimenopause is advisable to detect loss early when intervention is most effective.
Men also express aromatase in bone tissue, and testosterone therapy outcomes differ by
rs1062033 genotype — indicating the variant's regulatory role in bone is not
sex-exclusive, though the effect is smaller and evidence thinner in men.
Interactions
rs1062033 interacts epistatically with the IL-10 promoter variant rs1800896 in
Alzheimer's disease risk — but only in women, with a synergy factor of 1.94 in
the Epistasis Project (1,757 AD cases, 6,294 controls). The proposed mechanism
involves local brain estrogen synthesis: aromatase is expressed in neurons and
astrocytes, and locally produced estradiol modulates neuroinflammatory signaling
via estrogen receptor beta. When aromatase activity is lower (CC genotype) AND
IL-10 production is impaired (rs1800896 risk allele), the combined inflammatory
environment in postmenopausal brain tissue may compound Alzheimer's risk beyond
either variant alone. This interaction is not yet actionable as an independent
clinical signal, but it illustrates the reach of aromatase regulation beyond bone.
rs700518 (also in CYP19A1, ~12 kb away) is the most studied bone-BMD variant in
this gene and has a more robust evidence base for BMD effects in both sexes. Both
variants modulate aromatase expression in bone but through distinct regulatory
elements; their combined effect has not been formally characterized.
Alla genotyper
Two copies of the G allele — higher aromatase regulatory activity in peripheral tissues
You carry two copies of the G allele at this regulatory position in the aromatase gene. The G allele drives stronger CEBPβ-responsive transcription of CYP19A1 in peripheral tissues including bone, resulting in higher local estrogen synthesis from androgen precursors. In a Spanish cohort of 1,163 postmenopausal women, GG homozygotes had the highest bone mineral density among the three genotypes, with opposing homozygotes differing by up to 7.3% in older postmenopausal women. About 21% of people globally carry this genotype, with higher frequency in European and East Asian populations (~20–25%). The G allele was also independently associated with significantly reduced bladder cancer risk.
One copy each of the C and G alleles — moderately altered aromatase regulation
You carry one C allele and one G allele at this CYP19A1 regulatory site. The two alleles differ in how strongly they recruit the CEBPβ transcription factor to drive aromatase expression in bone and other peripheral tissues. Heterozygotes are expected to have intermediate local aromatase activity — higher than CC individuals but lower than GG homozygotes. About 47% of people of European descent share this genotype. The bone mineral density effect observed in postmenopausal women falls between the two homozygous groups; the practical difference from GG is modest.
Two copies of the C allele — reduced aromatase regulatory activity in bone tissue
You carry two copies of the C allele at this CYP19A1 regulatory position. Both copies drive lower CEBPβ-responsive transcription of the aromatase gene in peripheral tissues, including bone. This translates to reduced local estrogen synthesis — particularly relevant after menopause, when peripheral aromatization becomes the dominant source of bone-protective estrogen. About 32% of people globally share this genotype (though it is more common in African populations, where it reaches ~76% frequency). Postmenopausal women with this genotype showed up to 7.3% lower BMD compared with GG carriers in women older than 67 in a Spanish cohort of 1,163 women.